NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it has entered into a subscription agreement to raise $500 million in gross proceeds to help fund its purchase of Life Technologies.

Under the terms of the agreement, which Thermo Fisher disclosed in a document filed with the US Securities and Exchange Commission, the company will issue in a private placement up to approximately 5.3 million shares of its common stock to Temasek at $95 per share. The share price will be adjusted depending on when the investment closes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Sciencethis week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.